Investor Notes - Phillip Securities (HK) Ltd
Past Investor Notes *Advertisement*
Phillip Home Send to Friends Free Subscription Give Comments 中文版
3 Sep, 2018 (Monday)

MicroPort Scientific Corporation(853) is engaged in the development, manufacture and sale of medical devices, which include orthopedics devices, cardiovascular devices, drug eluting stents, cardiac rhythm management devices, endovascular devices, TAA/AAA stent grafts, electrophysiology devices, neurovascular devices, surgical devices. For the six months ended 30 June 2018, the Group recorded revenue of US$309 million, representing a growth of 42.6% as compared to the corresponding period in 2017. Besides the contribution from the CRM business acquired from LivaNova, all existing business segments recorded satisfactory growth. (I do not hold the above stock)
Buy-in Price: $9.30, Target Price: $10.60, Cut Loss Price: $8.60

PING AN(2318)
In 1H18, Ping An achieved an operating profit attributable to shareholders of RMB59.3bn (+23.3% yoy). Net profit increased 31.9% yoy to RMB64.7bn. Net profit attributable to shareholders rose 33.8% yoy to RMB58.1bn. Given the fast growth in operating profit, Ping An is increasing cash dividends. An interim dividend of RMB0.62 per share will be paid in cash, up 24.0% yoy. The number of retail customers saw a strong growth of 25.2% yoy to 179mn. Each customer held 2.39 contracts on average, up 4.8% yoy. Operating profit per customer rose by 2.5% yoy to RMB281. The life and health insurance business recorded an operating profit of RMB35.6bn (+24.7% yoy). Net profit rose 44.2% yoy to RMB34.4bn. The NBEV grew by 0.2% yoy to RMB38.7bn amid industry restructuring. The unannualized ROEV reached 17.6%. Sales agents increased by 5.5% yoy to 1.399mn.
Buy-in Price: $75.60, Target Price: $90.00, Cut Loss Price: $68.00

CSPC Pharmaceutical (1093.HK) - Comments on 18H1 Results

Investment Summary

CSPC announced 18H1 results last week with strong revenue and profit growth. We maintain EPS forecast of HK$0.59/0.78 for 18E/19E, and target price of HK$24.8 on the basis of a target P/E ratio 42x. (Closing price at 28 Aug 2018)

Business Overview

Financial review. Total sales increased by 49.8% yoy to HK$10.79bn in the first half, mainly due to the sustained strong growth of innovative drugs (now 45.2% of the total revenue), and recovery of Vitamin C business which also drive the profitability of this business up. The profit attributable to shareholders increased by 41.1% yoy to HK$1.85bn. Cash flows from operating activities climbed to HK$2.18bn (HK$1.27bn in 2017). Operation efficiency improves. Average turnover period of accounts receivable increased slightly from 40 days to 37 day, and inventory days dropped from 173 days to 150 days.

Escalated expenses. OPM dropped by 1.8pp due to rising selling and R&D expenses. R&D expenditure rose 112% yoy to HK$688mn, more than 60% of which was spent on innovative drug R&D, and some on conformity assessment and generics. In the next few years, CSPC will continue to invest heavily in innovative drugs thus we expect that R&D cost is expected to remain relatively high. Selling expenditure ratio rose to 33.35% in 18H1 from 25.8% in 17H1, mainly resulting from continued expansion of sales team and increased cost of academic promotion. According to company guidelines, the number of salesmen for NBP will increase to about 1500 by FY17 end, and that for Xuanning and Olaining will reach more than 600 respectively. Also CSPC proactively promotes the consistency evaluation of generic drugs. At present, products that have passed consistency evaluation include azithromycin tablets, tramadol hydrochloride tablets and captopril tablets, etc.

Innovative medicines. Innovative drugs achieved HK$48.7 in 18H1, up by 65% yoy. By products, NBP achieved sales revenue growth of 42.6% to HK$2.36bn, with 28% growth for capsules and 57.5% for injections. Albumin paclitaxel has come into market since Mar, which grows quickly realizing sales of HK$86mn yet. Albumin paclitaxel has now entered five provinces’ drug reimbursement list and covers 290 hospitals. Sales target according to Mgt was HK$300mn/1bn for 18E/19E. Revenue of Oulaining increased by 78% to HK$1bn, and that of Xuanning injections increased by 105% to HK$580mn.

Generic medicines. Sales of generic drugs reached HK$3.31bn, a notable increase of 42.3%, mainly because the company continues to intensify promotion of non-antibiotic drugs and expand oral products for chronic diseases. High-end antibiotic products (Meropenem for injection) and health products (vitamin C buccal tablets) also maintained rapid growth. The company indicated that it would consider divestiture or sale of VC business. Currently, VC business provides stable cash flow for the group, and has higher than industry average profit margin. While its gross margin will further increase, if the divestiture of Vitamin C business happens.

Valuation Thesis & Risks

We maintain target price at HK$24.8. Solid 18H1 results further prove its growth momentum that coming from expanding salesman team and newly-launched drugs. We remain TP of HK$24.8 to factor into concerns about improving expenditures (for sales and R&D). Risks include: R&D failure; Slow than expected sales growth; Rising expenses.


Click Here for PDF format...

Recommendation on 3-9-2018
Price on Recommendation Date$ 20.450
Suggested purchase priceN/A
Target Price$ 24.800
Writer Info
Eurus Zhou
(Research Analyst)
Tel: +852 2277 6515

Local Index
       Index    Change   Change%

World Index
       Index    Change   Change%

A-H spread
Stock Code H share
A share
H share

Oversea Research Reports

Investment Service Centre

Enquiry : 2277 6666 OR
If you cannot read this e-mail in the proper format, please click here to view the web version.

Information contained herein is based on sources that Phillip Securities (Hong Kong) Limited and/or its affiliates ( the “Group”) believe to be accurate. The Group does not bear responsibility for any loss occasioned by reliance placed upon the contents hereof. The Group (or its employees) may have interests in relevant investment products. For details of different products’ risks, please view the Risk Disclosures Statement on

If you DO NOT wish to receive further marketing emails from us, please click HERE to opt-out.

版權所有, 翻印必究。

Copyright(C) 2018 Phillip Securities (HK) Ltd. All Rights Reserved.